| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Departments of Medicine*
and Clinical
Pathology,
Stockholm Söder Hospital,
Stockholm, Sweden; the Department of
Hematology,
Huddinge University Hospital,
Huddinge, Sweden; and the Departments of Environmental Health, Harvard
School of Public Health§
and
Children’s Hospital,¶
Boston, Massachusetts
Several studies have emphasized the significance of neoangiogenesis for tumor growth and progression, but few have focused on malignant hematological disorders. We studied vascular density and architecture in bone marrow samples of patients with chronic myeloproliferative disease (MPD). Vascular structures were immunostained (for von Willebrand factor/FVIII-RAG, CD 31/PECAM or Ulex europeus I for vessels and for vascular endothelial growth factor, VEGF) in samples from patients with polycythemia vera (PV) (n = 7), chronic myelocytic leukemia (CML) (n = 9), and myelofibrosis (MF) (n = 6) when diagnosed and were compared with normal bone marrow specimens (n = 9). We observed that the mean (± SD) vessel count per high-power microscopy field (HPF) was 5.3 (± 2.1) in normal bone marrow, 5.9 (± 2.1) in PV, 10.8 (± 3.2) in CML, and 14.4 (± 5.5) in MF (P < 0.001 for CMP and MF versus controls). Confocal microscopy, including three-dimensional reconstructions of the blood vessel architecture, confirmed this increased vessel density and revealed tortuous vessel architecture and increased branching in the MPD, particularly in CML and MF. Furthermore, the number of VEGF-positive bone marrow cells was increased in CML and, particularly, in MF. Numbers of VEGF-positive cells and vessels per HPF correlated significantly (r = 0.41; P = 0.037). Thus the myeloproliferative diseases PV, CML, and MF exhibit neoangiogenesis that is related to diagnosis.
This article has been cited by other articles:
 |
|
 |
|
  A. Tefferi Primary myelofibrosis and its paraneoplastic stromal effects Haematologica, May 1, 2007; 92(5): 577 - 579. [Full Text] [PDF]
|
|
|
|
|
|
E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows Haematologica, May 1, 2007; 92(5): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, M. Guo, Y.-B. Xu, D. Li, Z.-N. Zhou, Y.-L. Wu, Z. Chen, S. C. Kogan, and G.-Q. Chen Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia Blood, January 15, 2006; 107(2): 698 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gerli, C. Vanelli, O. Turri, M. Erario, A. Gardellini, M. Pugliano, and M. L. Biondi SDF1-3'A Gene Polymorphism Is Associated with Chronic Myeloproliferative Disease and Thrombotic Events Clin. Chem., December 1, 2005; 51(12): 2411 - 2414. [Full Text] [PDF]
|
|
|
|
|
|
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kvasnicka, J. Thiele, P. Staib, A. Schmitt-Graeff, M. Griesshammer, J. Klose, K. Engels, and S. Kriener Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy Blood, May 1, 2004; 103(9): 3549 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rumpel, T. Friedrich, and M. W. N. Deininger Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase Blood, June 1, 2003; 101(11): 4641 - 4643. [Full Text] [PDF]
|
|
|
|
|
|
M. Mayerhofer, P. Valent, W. R. Sperr, J. D. Griffin, and C. Sillaber BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin Blood, November 15, 2002; 100(10): 3767 - 3775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood, October 16, 2002; 100(9): 3344 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verstovsek, H. Kantarjian, T. Manshouri, J. Cortes, F. J. Giles, A. Rogers, and M. Albitar Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia Blood, March 15, 2002; 99(6): 2265 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. List Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giles The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bianco, M. Riminucci, S. Gronthos, and P. G. Robey Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential Applications Stem Cells, May 1, 2001; 19(3): 180 - 192. [Abstract] [Full Text]
|
|
|
|
|
|
A. Janowska-Wieczorek, M. Majka, J. Ratajczak, and M. Z. Ratajczak Autocrine/Paracrine Mechanisms in Human Hematopoiesis Stem Cells, February 1, 2001; 19(2): 99 - 107. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
